CNS Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CNSP Nasdaq 2834 www.cnspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287 - Jun 24th, 2025 7:15 am
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit - Jun 5th, 2025 6:05 am
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 16th, 2025 6:05 am
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - May 13th, 2025 7:35 am
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 - May 13th, 2025 5:00 am
CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year - Apr 2nd, 2025 6:46 am
CNS Pharmaceuticals Reports Full Year 2024 Financial Results - Apr 1st, 2025 6:05 am
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven? - Mar 26th, 2025 7:01 am
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme - Mar 25th, 2025 6:00 am
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing - Feb 26th, 2025 7:05 am
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum - Feb 20th, 2025 7:00 am
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Feb 19th, 2025 7:00 am
CNS Pharmaceuticals Announces Reverse Stock Split - Feb 19th, 2025 6:30 am
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit - Feb 18th, 2025 7:00 am
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference - Feb 10th, 2025 6:00 am
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 - Dec 5th, 2024 7:10 am
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy - Nov 25th, 2024 7:00 am
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) - Nov 18th, 2024 6:55 am
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results - Nov 15th, 2024 7:10 am
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment - Nov 4th, 2024 7:15 am